Research Article
Prognostic Factors of Peritoneal Metastases from Colorectal Cancer following Cytoreductive Surgery and Perioperative Chemotherapy
Table 1
Patients and tumor characteristics.
| Characteristics | |
| Gender | | Male | 68 | Female | 74 | Tumor location | | Colon | 6 | Rectum | 136 | Lymph node status | | N0 | 50 | N1 | 64 | N2, N3 | 28 | Diagnosis of carcinomatosis | | Synchronous carcinomatosis | 59 | Metachronous carcinomatosis | 83 | Systemic chemotherapy prior to cytoreduction | | None | 32 | FOLFOX (+bevacizumab; BV) | 60 (24) | FOLFIRI (+BV or +cetuximab) | 17 (2, 5) | Xeloda (+oxaliplatin or +BV) | 17 (14, 5) | S1 (+paclitaxel) | 10 (5) | Others (IRIS#, TJ$, SOX&, and HIPEC¥) | 6 |
|
|
IRIS: Irinotecan +S1, $TJ: taxol + CBDCA.
&SOX: S1+ Oxaliplatin. ¥HIPEC: hyperthermic intraperitoneal chemotherapy.
|